Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5976371 | 0.88 | SOD1 (0.39) | SOD1IDO1KDM1AFGFR1FGFR2 | |
| SCHEMBL27870127 | 0.86 | MAPT (0.43) | — | |
| SCHEMBL22645667 | 0.85 | SOD1 (0.37) | SOD1 | |
| SCHEMBL1547744 | 0.80 | SOD1 (0.42) | SOD1IDO1CA12CA1CA9 | |
| SCHEMBL2003939 | 0.79 | MAOB (0.49) | — | |
| SCHEMBL17672561 | 0.77 | GRM5 (0.38) | — | |
| SCHEMBL3054211 | 0.76 | SOD1 (0.40) | SOD1IDO1KDM1AFGFR1FGFR2 | |
| SCHEMBL3922161 | 0.76 | ALDH1A1 (0.48) | SOD1CA12CA1CA9 | |
| SCHEMBL6793710 | 0.76 | KAT6A (0.43) | SOD1KAT6AFGFR1FGFR2CA12 | |
| SCHEMBL4023626 | 0.76 | SOD1 (0.40) | SOD1IDO1KDM1AFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| US-7015345-B2 | Propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1484316-A1 | NOVEL PROPIONIC ACID DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040072690-A1 | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072690-A1 | Novel propionic acid derivatives | PNLIP, LIPC, GPR119 | SOD1 2511/4885IDO1 4434/4885KAT6A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.